Cart
sales@molnova.com
CK7
CAS No. 507487-89-0
CK7( [4-(2-Amino-4-methyl-thiazol-5-YL)-pyrimidin-2-YL]-(3-nitro-phenyl)-amine )
Catalog No. M28803 CAS No. 507487-89-0
CK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 160 | Get Quote |
|
| 10MG | 259 | Get Quote |
|
| 25MG | 515 | Get Quote |
|
| 50MG | 740 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 500MG | 2052 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCK7
-
NoteResearch use only, not for human use.
-
Brief DescriptionCK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
DescriptionCK7, a?Cdk2/9?inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
-
In Vitro——
-
In Vivo——
-
Synonyms[4-(2-Amino-4-methyl-thiazol-5-YL)-pyrimidin-2-YL]-(3-nitro-phenyl)-amine
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorΔ5D
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number507487-89-0
-
Formula Weight655.69
-
Molecular FormulaC28H23N12O4S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (38.07 mM)
-
SMILESCc1c(-c2nc(Nc3cc([N+]([O-])=O)ccc3)ncc2)sc(N)n1Cc1c(-c2nc(Nc3cc([N+]([O-])=O)ccc3)ncc2)sc(N)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time Ikuo Miyahisa, Hideo Suzuki, Atsushi Mizukami, Yukiya Tanaka, Midori Ono, Mark S. Hixon, and Junji Matsui Publication Date (Web): August 10, 2016 (Letter)
molnova catalog
related products
-
Ro-3306
RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.
-
CDK inhibitor E9
CDK inhibitor E9 is a novel CDK inhibitor that can overcomes ABC-mediated resistance of THZ1, functions as a potent, non-covalent inhibitor of CDK9 and a covalent inhibitor of CDK12.
-
CDK4/6-IN-2
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
